NCT05985681View on ClinicalTrials.gov

Testing RG1-VLP Vaccine to Prevent HPV-related Cancers

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 27, 2025

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2027

Conditions
Human Papillomavirus-Related Carcinoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample and vaginal swab collection

BIOLOGICAL

HPV16 RG1 VLP Vaccine

Given IM

OTHER

Questionnaire Administration

Ancillary studies

BIOLOGICAL

Recombinant Human Papillomavirus Nonavalent Vaccine

Given via injection

Trial Locations (5)

10305

WITHDRAWN

Staten Island University Hospital, Staten Island

21287

WITHDRAWN

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

35233

WITHDRAWN

University of Alabama at Birmingham Cancer Center, Birmingham

53792

RECRUITING

University of Wisconsin Carbone Cancer Center - University Hospital, Madison

A-1090

NOT_YET_RECRUITING

Medical University Vienna, Vienna

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH